Abstract Body

Background

The aim of this study was to characterize subtypes circulation and transmitted drug resistance (TDR) in Italy by next-generation sequencing (NGS).

Methods

Routine plasma HIV-1 RNA NGS genotyping data were collected from newly diagnosed individuals over 2021-2024. TDR for PI, NRTI, NNRTI and INI, and genotypic susceptibility were evaluated through HIVdb (ver.9.6) with NGS set at 10% and 20%. Subtype and transmission clusters (TC) were determined through the Maximum Likelihood phylogeny based on the GTR+F+R9 model.

Results

473 PLWH (median age 41 [31-51], 77.6% males) were included; 56.2% of them harboured non-B strains (CRF02_AG [15.6%]; CRFs BF [13.1%]; F1 [5.1%]; A1/A6 [7.4%]; Others [15.0%]). TDR prevalence to any class was 12.3% at Sanger like NGS-setting (>20%) and slightly increased (15.9%) at 10% setting. PI-TDR was low regardless of NGS-settings (2.7% and 2.3%); NRTI-TDR and NNRTI-TDR was 4.0% and 6.8% at 20% NGS-setting and slightly increased at 10% NGS-setting (5.9% and 7.6%). INI-TDR was very low at both NGS-setting (20%: 0.2%; 10%: 1.1%). TDR was higher in B compared to non-B subtypes, particularly for NRTI (Figure 1A).

Concerning genotypic susceptibility, the currently recommended first-line regimens based on high genetic barrier drugs showed full activity in >97% of individuals, regardless of NGS-setting and subtypes. These proportions were lower for rilpivirine- (≥86%) and raltegravir-based (≥95%) regimen regardless NGS-setting. Rilpivirine susceptibility was lower in the B-subtype subset, while raltegravir was predicted less active in non-B subtypes (Figure 1B).

Concerning transmission networks, a total of 35 TC were detected: 27 pairs, 7 small clusters (3-8 sequences), and 1 large cluster (9 sequences). Among them, 23 were found in non-B subtypes (60%). 

Six TC had RTI-TDR including: 3 subtype B and 2 CRF02_AG TC with thymidine analogue mutations; 1 CRF31_BC TC with the NNRTI mutation K103N. Of note, TDR was detected as minority mutations in three out of six TC.

Conclusions

A high proportion of HIV-1 non-B subtypes circulate in Italy. TDR prevalence is around 16% using NGS set at 10%. However, the impact of the detected TDR on the susceptibility to currently recommended first-line regimens is negligible. NGS genotyping can improve the characterization of transmission networks of resistance, allowing the detection of TC harbouring minority-resistant species not detectable with Sanger.